Document |
Document Title |
WO/2023/211063A1 |
The present invention relates to an organic compound employed in an organic layer, such as a hole transport layer or an electron blocking layer, in an organic light-emitting element. The organic compound according to the present inventio...
|
WO/2023/207375A1 |
The present application relates to a nitrogen-containing compound, an electronic element, and an electronic device. The nitrogen-containing compound has a structure represented by formula I, and can improve the performance of electronic ...
|
WO/2023/211213A1 |
The present invention relates to a novel organic compound and an organic electroluminescent device using same and, more specifically, to an organic compound having excellent electron transport and injection ability, light-emitting abilit...
|
WO/2023/210520A1 |
Provided are: a resist composition having favorable sensitivity, roughness characteristics, and etching resistance; a resist pattern formation method; and a new compound that is useful as a resin component for said resist composition. Th...
|
WO/2023/201423A1 |
The present application relates to indoline derivatives of general Formula (I), to processes for their preparation, to compositions comprising them and to their use in activation of a serotonin receptors in a cell, as well as to treating...
|
WO/2023/201421A1 |
The present application relates to indoline derivatives of general Formula (I), to processes for their preparation, to compositions comprising them and to their use in activation of a serotonin receptors in a cell, as well as to treating...
|
WO/2023/205173A1 |
Described herein are compounds that are glutaminyl-peptide cyclotransferase like (QPCTL) protein modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using su...
|
WO/2023/204694A1 |
The present invention relates to a heterocyclic compound represented by chemical formula 1, an organic light-emitting element comprising same, and a composition for an organic layer.
|
WO/2023/202377A1 |
The present application provides a deuterated composition, an organic electroluminescent device, and a display apparatus. The deuterated composition comprises a deuterated mixture prepared from compound A by means of a deuteration reacti...
|
WO/2023/202583A1 |
Disclosed are an FXR regulator and use thereof, and specifically disclosed are a compound represented by formula I, or a stereoisomer, a prodrug, a crystal form, a pharmaceutically acceptable salt, a pharmaceutically acceptable solvate, ...
|
WO/2023/204386A1 |
The present specification provides a heterocyclic compound, an organic light-emitting device comprising same, and a composition for an organic layer of an organic light-emitting device.
|
WO/2023/202664A1 |
Disclosed herein are fused bi-cyclic compounds used as Small Molecule IL-17A Modulators. Disclosed herein is the use of these Small Molecule IL-17A Modulators for the use of decreasing IL-17 activity by inhibition, and the use of such co...
|
WO/2023/198901A1 |
Disclosed herein are compounds of the formula (I), or pharmaceutically acceptable salts thereof formula (I) wherein R3 represents a hydrogen atom, a -COOH group or a -OH group; R3' and R3" independently represent a hydrogen atom, a methy...
|
WO/2023/200226A1 |
The present specification provides a compound represented by chemical formula 1 and an organic light-emitting device including the compound.
|
WO/2023/200282A1 |
The present invention provides a novel compound and an organic light-emitting element comprising same.
|
WO/2023/200225A1 |
The present specification provides a compound represented by chemical formula 1 and an organic light-emitting device comprising same.
|
WO/2023/198903A1 |
Disclosed herein are compounds of the formula (I), or pharmaceutically acceptable salts thereof: wherein R1 and R2 independently represent a hydrogen atom or a deuterium atom; R3 represents a hydrogen atom, a -COOH group or a -OH group; ...
|
WO/2023/198879A1 |
Disclosed herein are compounds of the formula (I), or pharmaceutically acceptable salts thereof, wherein R1 and R2 represent a hydrogen atom or a deuterium atom; R3 represents a hydrogen atom, a -COOH group or a -OH group; R3' and R3" re...
|
WO/2023/198905A1 |
Disclosed herein are compounds of the formula (I), or pharmaceutically acceptable salts thereof, wherein R1 and R2 represent hydrogen or deuterium; R3 represents hydrogen, -COOH or -OH; R3' and R3" represent hydrogen, methyl, methoxy, ch...
|
WO/2023/199091A1 |
The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. [Solving Means] A compound represented by the formula (I) is useful as an agent for the prophylaxis or treatment of narcolepsy.
|
WO/2023/196985A1 |
Disclosed herein are compounds of Formula (I): or a pharmaceutically acceptable salt thereof, wherein A and A' are each independently selected from the group consisting of: (a1), (a2), (a3), (4) and (a5) and B, B', X and Y have the meani...
|
WO/2023/193733A1 |
The present disclosure relates to the field of medicine. Specifically, provided in the present disclosure are a compound represented by formula I, and a tautomer, a stereoisomer, a hydrate, a solvate, and a pharmaceutically acceptable sa...
|
WO/2023/194895A1 |
This invention relates to novel compounds which are inhibitors of APOL1, pharmaceutical compositions containing the compounds, processes for their preparation, and uses thereof in therapy for the treatment of kidney diseases and sepsis.
|
WO/2023/195529A1 |
The present invention provides: a compound that exhibits a coronavirus 3CL protease inhibitory activity or a pharmaceutically acceptable salt thereof; and a pharmaceutical composition containing the same. The compound is represented by f...
|
WO/2023/195669A1 |
The present invention relates to a novel benzothiophene derivative and use thereof as a bromodomain extra-terminal (BET) inhibitor, and, more specifically, to a novel benzothiophene derivative compound of the following chemical formula 1...
|
WO/2023/195787A1 |
An organic compound represented by chemical formula 1 of the present invention can implement excellent hole transfer characteristics. In addition, at least one of a hole transport layer and a hole transport aid layer of an organic light ...
|
WO/2023/194458A1 |
The present invention relates to a compound of formula (I) or an enantiomer, diastereomer, N-oxide, solvate or pharmaceutically acceptable salt thereof. The present invention further relates to a compound of formula (I) for use in a meth...
|
WO/2023/195791A1 |
The present invention relates to a phenylpropenone backbone compound, which is a novel chromanone or a ring-opened form thereof, and a composition for preventing or treating multiple myeloma comprising same as an active ingredient. The c...
|
WO/2023/191353A1 |
The present specification relates to a heterocyclic compound of chemical formula 1, an organic light-emitting device comprising same, and a composition comprising same for forming an organic layer.
|
WO/2023/185078A1 |
The present invention relates to an organic compound, an electronic element and an electronic device. The structure of the organic compound is as shown in formula 1, and the organic compound can improve the performance of an electronic e...
|
WO/2023/191536A1 |
The present invention relates to a thiobenzimidazole derivative or a pharmaceutically acceptable salt thereof, and a composition for preventing or treating cancer, the composition comprising the derivative as an active ingredient. The th...
|
WO/2023/186023A1 |
The present invention belongs to the field of pharmaceutical chemistry. Specifically disclosed are a N-substituted quinolinone compound, a preparation method therefor and pharmaceutical use thereof. The compound of the present invention ...
|
WO/2023/191468A1 |
The present invention relates to nitrogen-containing heterocyclic compound derivatives and uses thereof. The compounds according to the present invention can exert therapeutic effects on various neurological disorders, such as neurodegen...
|
WO/2023/190987A1 |
Provided are: a compound represented by either formula (1) or formula (2) (where the symbols in formula (1) and formula (2) are as defined in the description); an organic electroluminescent element containing the compound; and an electro...
|
WO/2023/192578A1 |
The present invention relates to novel bifunctional compounds, as well as compositions thereof, which modulate KLHDC2 and/or function to recruit targeted proteins to KLHDC2 for degradation. These bifunctional compounds, which find utilit...
|
WO/2023/192506A1 |
Provided herein are compounds, compositions, and methods useful for modulating MALT1 and for treating related diseases, disorders, and conditions.
|
WO/2023/191469A1 |
The present invention relates to nitrogen-containing heterocyclic compounds having a phenyl group and uses thereof. The compounds, according to the present invention, effectively enhance synaptic plasticity without side-effects and thus ...
|
WO/2023/182899A1 |
The present invention relates to a novel compounds for use in treatment or prevention of cancer, in particular to use of said compounds as an inhibitors of interactions between TRF1-TIN2 or TRF2-TIN2 telomeric proteins.
|
WO/2023/179094A1 |
The present application relates to an organic compound, and an electronic component and an electronic device comprising same. The structural formula of the organic compound of the present application is shown as formula 1, the organic co...
|
WO/2023/182897A1 |
The present invention relates to a novel compounds for use in treatment or prevention of cancer, in particular to use of said compounds as an inhibitors of interactions between TRF1-TIN2 or TRF2-TIN2 telomeric proteins.
|
WO/2023/182836A1 |
The present specification relates to a compound of chemical formula 1 and an organic light-emitting device comprising same.
|
WO/2023/179758A1 |
Disclosed in the present application is a crystal of a fused tricyclic derivative or a pharmaceutically acceptable salt thereof; and specifically disclosed are a crystal of a compound of formula (I), a crystal of a pharmaceutically accep...
|
WO/2023/182775A1 |
The present invention pertains to: a novel aromatic heterocyclic compound that can be used in an organic light-emitting diode; and an organic light-emitting diode including same.
|
WO/2023/176609A1 |
This composition includes an infrared absorbing agent, a curable compound, and a solvent, wherein the infrared absorbing agent includes a compound represented by formula (1). Provided are a film, an optical filter, a solid-state imaging ...
|
WO/2023/177184A1 |
The present invention relates to: a compound, represented by chemical formula 1, for an organic optoelectronic device; an organic optoelectronic device comprising same; and a display device. The details of chemical formula 1 are as defin...
|
WO/2023/174235A1 |
Disclosed are a compound represented by formula (I) as a mutant isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) inhibitor, a preparation method therefor, and a pharmaceutical composition thereof. Also disclosed is a use of the described...
|
WO/2023/176957A1 |
The present invention provides a compound which is used for the treatment of a fungal infection, including a topical fungal infection and a systemic fungal infection, caused by fungi belonging to the genus Trichophyton, the genus Candida...
|
WO/2023/177568A1 |
The application relates to compounds of the general Formula (I) which act as cannabinoid receptor modulators useful for the treatment of complications arising from metabolic, inflammatory and fibrotic disorders.
|
WO/2023/170025A1 |
The present invention relates to compounds of general formula (I) inhibiting lysophosphatidic acid receptor 1 (LPA1), particularly the invention relates to compounds that are amido cyclopropyl derivatives, methods of preparing such compo...
|
WO/2023/169453A1 |
The present invention relates to a heteroaromatic ring-containing alkynyl compound, and a preparation method therefor and the use thereof. The heteroaromatic ring-containing alkynyl compound is a compound represented by a formula (I), or...
|